To reach Gesynta Pharma, please visit Contact.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Systemic sclerosis is an autoimmune disease hallmarked by chronic inflammation in the body’s smallest blood vessels.
Raynaud’s phenomenon affects most systemic sclerosis patients. It is often the first sign of the disease.
Half of systemic sclerosis patients develop difficult-to-heal digital ulcers, hampering many everyday activities.
Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.